Airway clearance management in people with bronchiectasis: data from the European Bronchiectasis Registry (EMBARC).


Journal

The European respiratory journal
ISSN: 1399-3003
Titre abrégé: Eur Respir J
Pays: England
ID NLM: 8803460

Informations de publication

Date de publication:
12 Apr 2024
Historique:
received: 03 10 2023
accepted: 02 03 2024
medline: 13 4 2024
pubmed: 13 4 2024
entrez: 12 4 2024
Statut: aheadofprint

Résumé

International guidelines recommend airway clearance management as one of the important pillars of bronchiectasis treatment. However, the extent to which airway clearance is used for people with bronchiectasis in Europe is unclear. The aim of the study was to identify the use of airway clearance management in patients with bronchiectasis across different countries and factors influencing airway clearance use. Prospective observational study using data from the EMBARC Registry between January 2015 and April 2022. Pre-specified options for airway clearance management were recorded, including airway clearance techniques, devices and use of mucoactive drugs. 16 723 people with bronchiectasis from 28 countries were included in the study. Mean age was 67 years (interquartile range 57-74 years, range 18-100 years) and 61% were females. Seventy-two percent of the participants reported daily sputum expectoration and 52% (95% CI 51-53%) of all participants reported using regular airway clearance management. Active cycle of breathing technique was used by 28% of the patients and airway clearance devices by 16% of participants. The frequency of airway clearance management and techniques used varied significantly between different countries. Patients who used airway clearance management had greater disease severity and worse symptoms, including a higher daily sputum volume compared to those who did not use it regularly. Mucoactive drugs were also more likely to be used in patients with more severe disease. Access to specialist respiratory physiotherapy was low throughout Europe, but particularly low in Eastern Europe. Only half of the people with bronchiectasis in Europe use airway clearance management. Use and access to devices, mucoactive drugs and specialist chest physiotherapy appears to be limited in many European countries.

Sections du résumé

BACKGROUND BACKGROUND
International guidelines recommend airway clearance management as one of the important pillars of bronchiectasis treatment. However, the extent to which airway clearance is used for people with bronchiectasis in Europe is unclear. The aim of the study was to identify the use of airway clearance management in patients with bronchiectasis across different countries and factors influencing airway clearance use.
METHODS METHODS
Prospective observational study using data from the EMBARC Registry between January 2015 and April 2022. Pre-specified options for airway clearance management were recorded, including airway clearance techniques, devices and use of mucoactive drugs.
RESULTS RESULTS
16 723 people with bronchiectasis from 28 countries were included in the study. Mean age was 67 years (interquartile range 57-74 years, range 18-100 years) and 61% were females. Seventy-two percent of the participants reported daily sputum expectoration and 52% (95% CI 51-53%) of all participants reported using regular airway clearance management. Active cycle of breathing technique was used by 28% of the patients and airway clearance devices by 16% of participants. The frequency of airway clearance management and techniques used varied significantly between different countries. Patients who used airway clearance management had greater disease severity and worse symptoms, including a higher daily sputum volume compared to those who did not use it regularly. Mucoactive drugs were also more likely to be used in patients with more severe disease. Access to specialist respiratory physiotherapy was low throughout Europe, but particularly low in Eastern Europe.
CONCLUSIONS CONCLUSIONS
Only half of the people with bronchiectasis in Europe use airway clearance management. Use and access to devices, mucoactive drugs and specialist chest physiotherapy appears to be limited in many European countries.

Identifiants

pubmed: 38609097
pii: 13993003.01689-2023
doi: 10.1183/13993003.01689-2023
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright ©The authors 2024. For reproduction rights and permissions contact permissions@ersnet.org.

Auteurs

Arietta Spinou (A)

Population Health Sciences, Faculty of Life Sciences and Medicine, King's College London, UK.
King's Centre for Lung Health, King's College London.
Arietta Spinou and Beatriz Herrero-Cortina contributed equally to this paper.

Beatriz Hererro-Cortina (B)

Universidad San Jorge, Zaragoza, Spain.
Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.
Instituto de Investigación Sanitaria (IIS) de Aragón, Zaragoza, Spain.
Arietta Spinou and Beatriz Herrero-Cortina contributed equally to this paper.

Stefano Aliberti (S)

IRCCS Humanitas Research Hospital, Respiratory Unit, Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Milan, Italy.

Pieter C Goeminne (PC)

Department of Respiratory Disease, AZ Nikolaas, Belgium.

Eva Polverino (E)

Pneumology Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, CIBERES, Barcelona, Spain.

Katerina Dimakou (K)

5th Respiratory Department and Bronchiectasis Unit, ''SOTIRIA" General Hospital of Chest Diseases Medical Practice: 86 Kifisias Ave, Athens, Greece.

Charles S Haworth (CS)

Cambridge Centre for Lung Infection, Royal Papworth Hospital and University of Cambridge, Cambridge, UK.

Michael R Loebinger (MR)

Royal Brompton and Harefield Hospitals and National Heart and Lung Institute, Imperial College London, UK.

Anthony De Soyza (A)

Population and Health Science Institute, Newcastle University and NIHR Biomedical Research Centre for Ageing, Freeman Hospital, Newcastle, UK.

Montserrat Vendrell (M)

Department of Pulmonology, Dr Trueta University Hospital, Girona Biomedical Research Institute (IDIBGI), University of Girona, Spain.

Pierre Regis Burgel (PR)

Department of Respiratory Medicine and French Cystic Fibrosis National Reference Center, Hôpital Cochin, AP-HP.
Université Paris Cité, Inserm U1016, Institut Cochin, Paris, France.

Melissa McDonnell (M)

Department of Respiratory Medicine, Galway University Hospital, Galway, Ireland.

Sivagurunathan Sutharsan (S)

Department of Pulmonary Medicine, University Hospital Essen - Ruhrlandklinik, Adult Cystic Fibrosis Center, University of Duisburg-Essen, Essen, Germany.

Sabina Skrgat (S)

University Medical Centre Ljubljana, Department of Pulmonary Diseases and Allergy, Ljubljana, Slovenia.
Medical Faculty, University of Ljubljana, Ljubljana, Slovenia.
University Clinic of Respiratory and Allergic Diseases Golnik, Golnik, Slovenia.

Luiz Maiz-Carro (L)

Chronic Bronchial Infection Unit, Pneumology Service, Ramón y Cajal Hospital, Alcalá de Henares University, Madrid, Spain.

Oriol Sibila (O)

Servicio de Neumología, Instituto Clínico de Respiratorio. IDIBAPS. Hospital Clínic, University of Barcelona, Spain.
CIBER de enfermedades respiratorias, ISCIII, Madrid, Spain.

Daiana Stolz (D)

Department of Pneumology, Faculty of Medicine, University of Freiburg, Germany.
Clinic of Respiratory Medicine and Pulmonary Cell Research, University of Basel, Switzerland.

Paula Kauppi (P)

Heart and Lung Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.

Apostolos Bossios (A)

Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden.
Division of Lung and Airway Research, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.

Adam T Hill (AT)

Royal Infirmary of Edinburgh, Department of Respiratory Medicine, Edinburgh, Edinburgh, UK.

Ian Clifton (I)

Leeds Teaching Hospitals NHS Trust, Leeds, UK.

Megan L Crichton (ML)

Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK.

Paul Walker (P)

Liverpool University Hospitals Foundation NHS Trust, Liverpool, UK.

Rosario Menendez (R)

Pneumology Department, Hospital Universitario y Politécnico La Fe-Instituto de Investigación Sanitaria La Fe, Valencia, Spain.

Sermin Borecki (S)

Cerrahpasa Medical Faculty, Department of Pulmonology Diseases, Istanbul University - Cerrahpasa, Istanbul, Turkey.

Dusanka Obradovic (D)

Faculty of Medicine Novi Sad, University of Novi Sad, Novi Sad, Serbia.
Institute for pulmonary diseases, , Sremska Kamenica, Serbia.

Adam Nowinski (A)

Department of Epidemiology, National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland.

Adelina Amorim (A)

Pulmonology Department - Centro Hospitalar Universitário S.João and Faculty of Medicine - University of Porto, Portugal.

Antoni Torres (A)

Department of Pulmonology Hospital Clinic of Barcelona, Spain University of Barcelona, CIBERES, IDIBAPS, ICREA Barcelona, Spain.

Natalie Lorent (N)

Department of Respiratory Diseases, University Hospitals Leuven, Leuven, Belgium.

Tobias Welte (T)

Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany.
Biomedical Research in End-Stage and Obstructive Lung Disease Hannover, German Center for Lung Research, Hannover, Germany.
European Reference Network on Rare and Complex Respiratory Diseases, Frankfurt, Germany.

Francesco Blasi (F)

Department of Pathophysiology and Transplantation, University of Milan, Italy.
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Mateja Jankovic Makek (MJ)

University of Zagreb School of Medicine and University Hospital Centre Zagreb, Croatia.
Clinic for Pulmonary diseases, University Hospital Centre Zagreb.

Michal Shteinberg (M)

Pulmonology Institute and CF Center, Carmel Medical Center, Haifa, Israel.
the B. Rappaport Faculty of Medicine, The Technion, Israel Institute of Technology, Haifa, Israel.

Wim Boersma (W)

Department of Pulmonary Diseases, Northwest Clinics, Alkmaar, Netherlands.

J Stuart Elborn (JS)

Faculty of Medicine, Health and Life Sciences, Queen's University, Belfast, UK.

James D Chalmers (JD)

Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK j.chalmers@dundee.ac.uk.

Felix C Ringshausen (FC)

Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany.
Biomedical Research in End-Stage and Obstructive Lung Disease Hannover, German Center for Lung Research, Hannover, Germany.
European Reference Network on Rare and Complex Respiratory Diseases, Frankfurt, Germany.

Classifications MeSH